@jelias

Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada

, , , and . Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 46 (8): e75--77 (April 2008)PMID: 18444843.
DOI: 10.1086/533469

Abstract

To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.

Links and resources

Tags